抗性-话题@MedSci

#抗性#

219篇内容 | 1623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666078, encodeId=5cdc16660e8bc, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物 , objectType=article, longId=210647, objectId=bb1d21064eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb1d21064eea, replyNumber=0, likeNumber=36, createdTime=2022-02-16, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb1d21064eea, moduleTitle=Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb1d21064eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666092, encodeId=f42f16660927d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Cell Death Dis：异常的癌基因ENC1表达会促进乳腺癌的放疗抗性, objectType=article, longId=215569, objectId=547e21556971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=547e21556971, replyNumber=0, likeNumber=32, createdTime=2022-06-24, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=547e21556971, moduleTitle=Cell Death Dis：异常的癌基因ENC1表达会促进乳腺癌的放疗抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=547e21556971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666088, encodeId=942416660880e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关, objectType=article, longId=215168, objectId=549b215168d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=549b215168d2, replyNumber=0, likeNumber=42, createdTime=2021-12-27, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=549b215168d2, moduleTitle=Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=549b215168d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666087, encodeId=1beb166608e1d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=35, createdTime=2022-04-14, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666095, encodeId=4444166609538, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？, objectType=article, longId=217432, objectId=267021e43210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267021e43210, replyNumber=0, likeNumber=0, createdTime=2022-05-23, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267021e43210, moduleTitle=Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=267021e43210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666101, encodeId=23821666101da, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, objectType=article, longId=221370, objectId=59592213e0c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59592213e0c8, replyNumber=0, likeNumber=40, createdTime=2021-12-09, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59592213e0c8, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59592213e0c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666094, encodeId=fd181666094b9, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=217362, objectId=4a1721e36230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a1721e36230, replyNumber=0, likeNumber=46, createdTime=2021-10-05, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a1721e36230, moduleTitle=NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a1721e36230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666077, encodeId=ae0e16660e720, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量 , objectType=article, longId=210272, objectId=e8832102e21a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8832102e21a, replyNumber=0, likeNumber=46, createdTime=2022-04-04, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8832102e21a, moduleTitle=Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8832102e21a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666076, encodeId=cf2216660e6eb, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Br J Cancer：上皮-间充质转换影响口腔鳞状细胞癌的放疗抗性和细胞侵袭, objectType=article, longId=209340, objectId=82b720934061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82b720934061, replyNumber=0, likeNumber=30, createdTime=2021-10-13, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82b720934061, moduleTitle=Br J Cancer：上皮-间充质转换影响口腔鳞状细胞癌的放疗抗性和细胞侵袭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82b720934061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, objectType=article, longId=215209, objectId=93d5215209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d5215209e6, replyNumber=0, likeNumber=29, createdTime=2021-12-17, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d5215209e6, moduleTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93d5215209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666091, encodeId=dcf216660911a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理, objectType=article, longId=215284, objectId=f0ec21528430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0ec21528430, replyNumber=0, likeNumber=52, createdTime=2022-02-26, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0ec21528430, moduleTitle=J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0ec21528430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666061, encodeId=c9cc1666061da, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , objectType=article, longId=204687, objectId=679620468e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679620468e97, replyNumber=0, likeNumber=29, createdTime=2021-05-11, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679620468e97, moduleTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679620468e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666074, encodeId=978116660e43b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能, objectType=article, longId=209038, objectId=d71e2090385c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71e2090385c, replyNumber=0, likeNumber=38, createdTime=2021-08-14, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71e2090385c, moduleTitle=Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71e2090385c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666057, encodeId=e37a166605ea2, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=47, createdTime=2021-07-18, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666070, encodeId=bef316660e02f, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, objectType=article, longId=207230, objectId=677220e230b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677220e230b0, replyNumber=0, likeNumber=48, createdTime=2021-08-02, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677220e230b0, moduleTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=677220e230b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666068, encodeId=a1fa166606896, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=48, createdTime=2021-11-01, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666073, encodeId=e29416660e393, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, objectType=article, longId=208515, objectId=d0982085157d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0982085157d, replyNumber=0, likeNumber=34, createdTime=2021-06-24, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0982085157d, moduleTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0982085157d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666055, encodeId=57da1666055ac, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Prostate：去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移, objectType=article, longId=202452, objectId=4259202452b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4259202452b7, replyNumber=0, likeNumber=45, createdTime=2021-03-13, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4259202452b7, moduleTitle=Prostate：去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4259202452b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666058, encodeId=f11216660586d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=PNAS：RNA结合蛋白DDX3介导雄激素受体的转录后调控：去势抗性的一个机制 , objectType=article, longId=203198, objectId=16052031988d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16052031988d, replyNumber=0, likeNumber=42, createdTime=2021-05-10, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16052031988d, moduleTitle=PNAS：RNA结合蛋白DDX3介导雄激素受体的转录后调控：去势抗性的一个机制 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16052031988d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666060, encodeId=de8416660609c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌患者中CTCs和tdEVs的自动计数和表型特征分析 , objectType=article, longId=204403, objectId=1aa720440321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aa720440321, replyNumber=0, likeNumber=52, createdTime=2021-08-05, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aa720440321, moduleTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌患者中CTCs和tdEVs的自动计数和表型特征分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aa720440321)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗性

2020-05-29

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物

2022-02-16

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Cell Death Dis：异常的癌基因ENC1表达会促进乳腺癌的放疗抗性

2022-06-24

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关

2021-12-27

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2022-04-14

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？

2022-05-23

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性

2021-12-09

yige2012 (审核中...)

前往app查看评论内容

#抗性#

NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌

2021-10-05

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量

2022-04-04

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Br J Cancer：上皮-间充质转换影响口腔鳞状细胞癌的放疗抗性和细胞侵袭

2021-10-13

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-12-17

yige2012 (审核中...)

前往app查看评论内容

#抗性#

J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理

2022-02-26

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

2021-05-11

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能

2021-08-14

yige2012 (审核中...)

前往app查看评论内容

#抗性#

NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌

2021-07-18

yige2012 (审核中...)

前往app查看评论内容

#抗性#

ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）

2021-08-02

yige2012 (审核中...)

前往app查看评论内容

#抗性#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-11-01

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验

2021-06-24

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Prostate：去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移

2021-03-13

yige2012 (审核中...)

前往app查看评论内容

#抗性#

PNAS：RNA结合蛋白DDX3介导雄激素受体的转录后调控：去势抗性的一个机制

2021-05-10

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Prostate Cancer P D：转移去势抵抗性前列腺癌患者中CTCs和tdEVs的自动计数和表型特征分析

2021-08-05

科室
- - 订阅+
  - 更多科室
工具
服务